265 related articles for article (PubMed ID: 25790038)
21. Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma.
Duns G; van den Berg E; van Duivenbode I; Osinga J; Hollema H; Hofstra RM; Kok K
Cancer Res; 2010 Jun; 70(11):4287-91. PubMed ID: 20501857
[TBL] [Abstract][Full Text] [Related]
22. MET alterations in biphasic squamoid alveolar papillary renal cell carcinomas and clinicopathological features.
Denize T; Just PA; Sibony M; Blons H; Timsit MO; Drossart T; Jakubowicz D; Broudin C; Morini A; Molina T; Vano Y; Auvray-Kuentz M; Richard S; Mejean A; Gimenez Roqueplo AP; Burnichon N; Verkarre V
Mod Pathol; 2021 Mar; 34(3):647-659. PubMed ID: 32770124
[TBL] [Abstract][Full Text] [Related]
23. Molecular genetic evidence for the independent origin of multifocal papillary tumors in patients with papillary renal cell carcinomas.
Jones TD; Eble JN; Wang M; MacLennan GT; Delahunt B; Brunelli M; Martignoni G; Lopez-Beltran A; Bonsib SM; Ulbright TM; Zhang S; Nigro K; Cheng L
Clin Cancer Res; 2005 Oct; 11(20):7226-33. PubMed ID: 16243792
[TBL] [Abstract][Full Text] [Related]
24. Dismantling papillary renal cell carcinoma classification: The heterogeneity of genetic profiles suggests several independent diseases.
Marsaud A; Dadone B; Ambrosetti D; Baudoin C; Chamorey E; Rouleau E; Lefol C; Roussel JF; Fabas T; Cristofari G; Carpentier X; Michiels JF; Amiel J; Pedeutour F
Genes Chromosomes Cancer; 2015 Jun; 54(6):369-82. PubMed ID: 25820192
[TBL] [Abstract][Full Text] [Related]
25. The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer.
Liao L; Testa JR; Yang H
Cancer Genet; 2015 May; 208(5):206-14. PubMed ID: 25873528
[TBL] [Abstract][Full Text] [Related]
26. Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma.
Becerra MF; Reznik E; Redzematovic A; Tennenbaum DM; Kashan M; Ghanaat M; Casuscelli J; Manley B; Jonsson P; DiNatale RG; Blum KA; Durack JC; Solomon SB; Arcila ME; Bourque C; Socci N; Carlo MI; Lee CH; Voss MH; Feldman DR; Motzer RJ; Coleman JA; Russo P; Cheng EH; Hakimi AA; Hsieh JJ
Eur Urol Focus; 2018 Dec; 4(6):986-994. PubMed ID: 29066084
[TBL] [Abstract][Full Text] [Related]
27. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing.
Gerlinger M; Horswell S; Larkin J; Rowan AJ; Salm MP; Varela I; Fisher R; McGranahan N; Matthews N; Santos CR; Martinez P; Phillimore B; Begum S; Rabinowitz A; Spencer-Dene B; Gulati S; Bates PA; Stamp G; Pickering L; Gore M; Nicol DL; Hazell S; Futreal PA; Stewart A; Swanton C
Nat Genet; 2014 Mar; 46(3):225-233. PubMed ID: 24487277
[TBL] [Abstract][Full Text] [Related]
28. In silico DNA methylation analysis identifies potential prognostic biomarkers in type 2 papillary renal cell carcinoma.
Yang M; Hlady RA; Zhou D; Ho TH; Robertson KD
Cancer Med; 2019 Sep; 8(12):5760-5768. PubMed ID: 31361072
[TBL] [Abstract][Full Text] [Related]
29. Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma.
Gossage L; Murtaza M; Slatter AF; Lichtenstein CP; Warren A; Haynes B; Marass F; Roberts I; Shanahan SJ; Claas A; Dunham A; May AP; Rosenfeld N; Forshew T; Eisen T
Genes Chromosomes Cancer; 2014 Jan; 53(1):38-51. PubMed ID: 24166983
[TBL] [Abstract][Full Text] [Related]
30. Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC.
Ibragimova I; Maradeo ME; Dulaimi E; Cairns P
Epigenetics; 2013 May; 8(5):486-93. PubMed ID: 23644518
[TBL] [Abstract][Full Text] [Related]
31. Risk prediction for metastasis of clear cell renal cell carcinoma using digital multiplex ligation-dependent probe amplification.
Yoshikawa Y; Yamada Y; Emi M; Atanesyan L; Smout J; de Groot K; Savola S; Nakanishi-Shinkai Y; Kanematsu A; Nojima M; Ohmuraya M; Hashimoto-Tamaoki T; Yamamoto S
Cancer Sci; 2022 Jan; 113(1):297-307. PubMed ID: 34687579
[TBL] [Abstract][Full Text] [Related]
32. MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array.
Albiges L; Guegan J; Le Formal A; Verkarre V; Rioux-Leclercq N; Sibony M; Bernhard JC; Camparo P; Merabet Z; Molinie V; Allory Y; Orear C; Couvé S; Gad S; Patard JJ; Escudier B
Clin Cancer Res; 2014 Jul; 20(13):3411-21. PubMed ID: 24658158
[TBL] [Abstract][Full Text] [Related]
33. Dynamic reprogramming of DNA methylation in SETD2-deregulated renal cell carcinoma.
Tiedemann RL; Hlady RA; Hanavan PD; Lake DF; Tibes R; Lee JH; Choi JH; Ho TH; Robertson KD
Oncotarget; 2016 Jan; 7(2):1927-46. PubMed ID: 26646321
[TBL] [Abstract][Full Text] [Related]
34. Keap1/Nrf2 pathway in kidney cancer: frequent methylation of KEAP1 gene promoter in clear renal cell carcinoma.
Fabrizio FP; Costantini M; Copetti M; la Torre A; Sparaneo A; Fontana A; Poeta L; Gallucci M; Sentinelli S; Graziano P; Parente P; Pompeo V; De Salvo L; Simone G; Papalia R; Picardo F; Balsamo T; Flammia GP; Trombetta D; Pantalone A; Kok K; Paranita F; Muscarella LA; Fazio VM
Oncotarget; 2017 Feb; 8(7):11187-11198. PubMed ID: 28061437
[TBL] [Abstract][Full Text] [Related]
35. VHL and FHIT locus loss of heterozygosity is common in all renal cancer morphotypes but differs in pattern and prognostic significance.
Velickovic M; Delahunt B; Störkel S; Grebem SK
Cancer Res; 2001 Jun; 61(12):4815-9. PubMed ID: 11406557
[TBL] [Abstract][Full Text] [Related]
36. Papillary renal cell carcinoma with cytologic and molecular genetic features overlapping with renal oncocytoma: Analysis of 10 cases.
Michalova K; Steiner P; Alaghehbandan R; Trpkov K; Martinek P; Grossmann P; Montiel DP; Sperga M; Straka L; Prochazkova K; Cempirkova D; Horava V; Bulimbasic S; Pivovarcikova K; Daum O; Ondic O; Rotterova P; Michal M; Hora M; Hes O
Ann Diagn Pathol; 2018 Aug; 35():1-6. PubMed ID: 30072012
[TBL] [Abstract][Full Text] [Related]
37. Genomic organization and chromosomal localization of the human CUL2 gene and the role of von Hippel-Lindau tumor suppressor-binding protein (CUL2 and VBP1) mutation and loss in renal-cell carcinoma development.
Clifford SC; Walsh S; Hewson K; Green EK; Brinke A; Green PM; Gianelli F; Eng C; Maher ER
Genes Chromosomes Cancer; 1999 Sep; 26(1):20-8. PubMed ID: 10441001
[TBL] [Abstract][Full Text] [Related]
38.
Chiang YC; Park IY; Terzo EA; Tripathi DN; Mason FM; Fahey CC; Karki M; Shuster CB; Sohn BH; Chowdhury P; Powell RT; Ohi R; Tsai YS; de Cubas AA; Khan A; Davis IJ; Strahl BD; Parker JS; Dere R; Walker CL; Rathmell WK
Cancer Res; 2018 Jun; 78(12):3135-3146. PubMed ID: 29724720
[TBL] [Abstract][Full Text] [Related]
39. Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma.
Bi M; Zhao S; Said JW; Merino MJ; Adeniran AJ; Xie Z; Nawaf CB; Choi J; Belldegrun AS; Pantuck AJ; Kluger HM; Bilgüvar K; Lifton RP; Shuch B
Proc Natl Acad Sci U S A; 2016 Feb; 113(8):2170-5. PubMed ID: 26864202
[TBL] [Abstract][Full Text] [Related]
40. High-resolution analysis of DNA copy number alterations and gene expression in renal clear cell carcinoma.
Yoshimoto T; Matsuura K; Karnan S; Tagawa H; Nakada C; Tanigawa M; Tsukamoto Y; Uchida T; Kashima K; Akizuki S; Takeuchi I; Sato F; Mimata H; Seto M; Moriyama M
J Pathol; 2007 Dec; 213(4):392-401. PubMed ID: 17922474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
